Skip to main content

Utilization of Ibrexafungerp in Pregnant Patients: A Descriptive Analysis in TriNetX

    Basic Details
    Date Posted
    Medical Product

    This query is part of ongoing active monitoring activities for ibrexafungerp. Ibrexafungerp is an antifungal agent used to treat vulvovaginal candidiasis (VVC) in post‐menarchal women and is contraindicated for use in pregnancy due to findings of severe fetal toxicity. This query aims to identify early signaling of ibrexafungerp use in pregnant patients. 

    The study period includes data from June 1, 2020 to May 26, 2022 and contains data from 74 health care organizations (HCOs), provided through the TriNetX Live™ platform in their USA Network. We ran this query on June 23, 2022. 

    Additional Details
    FDA Center
    Time Period
    June 1, 2020 - May 26, 2022
    Analysis Type
    TriNetX Analysis
    Population / Cohort
    Females 15 years of age and older
    Data Sources
    TriNetX USA Network